lotuseast logo
OTCBB: LOTS
 
U.S. Chamber of Commerce Member 2006

Contact Us

Lotus Pharmaceuticals, Inc.
Mr. Adam Wasserman, CFO
7900 Glades Road, Suite 420
Boca Raton, Florida 33434
info@LotusEast.com

Telephone: (877) 801-0344
Facsimile: (954) 337-2204
meds

Lotus Pharmaceuticals, Inc.
c/o Liang Fang Pharmaceuticals Co., Ltd.
16 Cheng Zhuang Road, Feng Tai District
Beijing 100071 People's Republic of China

Telephone: (8610) 6389 9868
Facsimile: (8610) 6389 9867
Email: bjlfyy@163.com
Website: www.cnlfyy.com/English/home.asp

Attorney of Record:
Attorney of Record:
Schneider Weinberger & Beilly LLP
Contact: Jim Schneider, Esq.
2200 Corporate Blvd., N.W., Suite 210
Boca Raton, Florida 33431

Telephone: (561) 362-9595
Facsimile: (561) 362-9612
Email: jim@swblaw.net
Website: www.swblaw.net

Auditor of Record:
Sherb & Co., LLP
Contact: Elsa Sung
1900 NW Corporate Blvd.,
Suite 210
East Boca Raton, FL 33431

Telephone: (561) 886-4234
Facsimile: (561) 886-3330
Email: esung@Sherbcpa.com
Website: www.Sherbcpa.com
This website contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the company's business and financial results is included in the Company's filings, available via the United States Securities & Exchange Commission. Occasionally, the Company may select and post articles or opinions of third parties, with no known connection with the Company. These are considered expert or qualified writers about the Chinese economy and its various opportunities and pitfalls. The Company neither endorses nor rejects these views or content, and the articles are offered only for the readers' edification and personal analyses.